---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-447608"
form_type: "8-K"
ticker: "EVMN"
cik: "0002044725"
company_name: "Evommune, Inc."
filed_at: "2026-11-04T22:10:44+00:00"
generated_at: "2026-11-04T22:12:08.527096+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Evommune in-licenses Hinova's VAV1 degrader EVO570 for $20M cash, $10M warrants, up to $1.1B milestones

## Summary
- Evommune pays Hinova $20M cash plus pre-funded warrants for 1,262,413 shares ($10M) at $0.001 exercise, for $30M total upfront.
- Milestones up to ~$1.1B: $150M development/regulatory and $920M commercial, plus tiered royalties from mid-single-digit to low-double-digit on ex-Greater China net sales.
- Rights cover worldwide excluding Greater China, which Hinova retains; Phase 1 expected to begin imminently, with a Phase 2 rheumatoid arthritis trial planned for 2027.
- $30M private placement: 4,966,889 shares at $6.04 to investors including Adage, Balyasny, OrbiMed and Squadron; closing expected on or about November 6, 2026.
- Pro forma cash, cash equivalents and investments estimated at ~$292.3M after closing, sufficient to fund operations into the second half of 2029.

## SEC filing metadata
- accession: 0001193125-26-447608
- form_type: 8-K
- ticker: EVMN
- cik: 0002044725
- company_name: Evommune, Inc.
- filed_at: 2026-11-04T22:10:44+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2044725/000119312526447608/0001193125-26-447608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2044725/000119312526447608/evmn-20261104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-447608
- JSON: https://secwatch.observer/filing/0001193125-26-447608.json
- Plain text: https://secwatch.observer/filing/0001193125-26-447608.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.